

REMARKS

Applicants kindly request the amendment to Specification be entered. This amendment adds the priority claim. No new matter is being added.

Applicants note that Claim 21 was cancelled during PCT prosecution and was omitted in the published PCT application. Applicants also note that Claims 1, 22, 23 and 24 were amended during prosecution of the PCT application and the amended claims were published.


Applicants kindly request the amendments to the Claims indicated above be entered. Applicants are requesting the cancellation of Claims 21 (which was previously cancelled), 28-31. Applicants are currently amending Claims 1 and 26 to bring these claims into compliance with U.S. practice. Support for new Claims 32-42 can be found throughout the Application, and specifically on pages 13-14, and 45-46. Applicants submit that no new matter is being introduced.

Applicant authorizes the Commissioner to charge all fees due to Deposit Account 19-0134. Applicant also requests that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104 Florham Park
East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address. Thank you for your assistance with this matter.

Respectfully submitted,



David L. Marks
Attorney for Applicants
Reg. No. 37,881

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922

Date: December 15, 2004